215 related articles for article (PubMed ID: 10856769)
1. The role of small, dense low density lipoprotein (LDL): a new look.
Packard C; Caslake M; Shepherd J
Int J Cardiol; 2000 Jun; 74 Suppl 1():S17-22. PubMed ID: 10856769
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
3. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
8. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
[TBL] [Abstract][Full Text] [Related]
9. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Bruckert E; Dejager S; Chapman MJ
Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
[TBL] [Abstract][Full Text] [Related]
10. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV
Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
[TBL] [Abstract][Full Text] [Related]
13. Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB.
Tsimihodimos V; Karabina SA; Tambaki A; Bairaktari E; Achimastos A; Tselepis A; Elisaf M
J Cardiovasc Pharmacol; 2003 Aug; 42(2):304-10. PubMed ID: 12883336
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
[TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Geiss HC; Otto C; Schwandt P; Parhofer KG
Metabolism; 2001 Aug; 50(8):983-8. PubMed ID: 11474489
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
Kucera M; Oravec S; Hirnerova E; Huckova N; Celecova Z; Gaspar L; Banach M
Angiology; 2014 Oct; 65(9):794-9. PubMed ID: 24163116
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Ikejiri A; Hirano T; Murayama S; Yoshino G; Gushiken N; Hyodo T; Taira T; Adachi M
Metabolism; 2004 Sep; 53(9):1113-7. PubMed ID: 15334369
[TBL] [Abstract][Full Text] [Related]
19. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
20. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Xu RX; Guo YL; Li XL; Li S; Li JJ
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
